Rami Kotb, Marc Geirnaert, Emily Rimmer, Vi Dao, Jayne Kasian, Leonard Minuk, Ivan Landego
{"title":"Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma","authors":"Rami Kotb, Marc Geirnaert, Emily Rimmer, Vi Dao, Jayne Kasian, Leonard Minuk, Ivan Landego","doi":"10.1016/j.clml.2025.01.022","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Isatuximab-based combinations are widely used to treat patients with relapsed or refractory multiple myeloma, and will soon become part of the standard first-line therapies in transplant-eligible and transplant-ineligible newly diagnosed patients. Isatuximab is currently approved for intravenous fixed volume (250ml) administration, with a maximum infusion rate of 200 ml/h and at least 75 minutes required for 1 administration. A recent clinical trial suggested the safety of a faster, 30-minute administration of isatuximab. Other trials are ongoing. Based on this early data as well as previous experience with monoclonal antibody therapies, the rapid, 30-minutes intravenous isatuximab administration was adopted at our institution as standard of care.</div></div><div><h3>Methodology</h3><div>We here report the early real-world data on this new standard.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages e510-e512"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265025000394","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Isatuximab-based combinations are widely used to treat patients with relapsed or refractory multiple myeloma, and will soon become part of the standard first-line therapies in transplant-eligible and transplant-ineligible newly diagnosed patients. Isatuximab is currently approved for intravenous fixed volume (250ml) administration, with a maximum infusion rate of 200 ml/h and at least 75 minutes required for 1 administration. A recent clinical trial suggested the safety of a faster, 30-minute administration of isatuximab. Other trials are ongoing. Based on this early data as well as previous experience with monoclonal antibody therapies, the rapid, 30-minutes intravenous isatuximab administration was adopted at our institution as standard of care.
Methodology
We here report the early real-world data on this new standard.
期刊介绍：
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
